XOMA will present at the next investor conferences



EMERYVILLE, Calif., December 21, 2021 (GLOBE NEWSWIRE) – XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today Its CEO, Jim Neal, will be presenting at the following upcoming investor conferences:

  • Biotech Showcase 2022 held virtually January 10-12 and January 17-19, 2022. Mr. Neal will hold a fireside conversation titled “Royalty Licensing: An Often Ignored Economic Asset”. Monday, Jan. 10, 2022 at 10:30 a.m. PT.
  • HC Wainwright BioConnect Virtual Conference held January 10-13, 2022. The presentation will be available on demand from January 10, 2022 at 4:00 a.m. PT and can be viewed at https://bit.ly/ 3DWWNs8. The presentation can also be viewed by visiting the Investor Relations section of the Company’s website at www.xoma.com. A replay of the presentation will be available and archived on the site for 90 days after the event.

About XOMA Corporation
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotechnology companies achieve their goal of improving human health. XOMA acquires the future economic potential associated with pre-commercial therapeutic candidates who have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the Future Economy, the Vendor receives non-dilutive, non-recourse funding that they can use to advance their internal drug candidate (s) or for general corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economic benefits associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.

Forward-looking statements / explanatory notes
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the potential of the portfolio of partnership programs. and technologies licensed from XOMA generating milestone and royalty revenue over time, growth in its asset portfolio and leadership. In some cases, you can identify these forward-looking statements by words such as “anticipate”, “intend”, “believe”, “estimate”, “plan”, “seek”, “plan”, “‘expect”. “,” Can, “will”, “would”, “could” or “should”, the negative of these terms or similar expressions. These forward-looking statements are not guarantees of XOMA’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions which may not prove to be accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those relating to our product candidates. subject to license agreements are still under development, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or continue to be, a viable market for the products in which we have ownership or royalty rights; if the therapeutic product candidates for which we hold a royalty do not receive regulatory approval, our third party licensees will not be able to commercialize them, and the impact on the global economy due to the COVID pandemic -19. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA’s most recent filing on Form 10-Q and other SEC documents. Consider these risks carefully when considering the outlook for XOMA. Any forward-looking statements in this press release represent XOMA’s beliefs and assumptions only as of the date of this press release and should not be taken to represent its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.

EXPLICATIVE NOTE: Any reference to the “portfolio” in this press release refers strictly to the milestone and / or royalty rights associated with a basket of pharmaceutical products in development. Any reference to “assets” in this press release refers strictly to the milestone and / or royalty rights associated with individual pharmaceutical products under development.

As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio are experimental compounds. Efficacy and safety have not been established. There is no guarantee that any of these assets will become commercially available.

Investor contacts:
Juliane Snowden Justin frantz
XOMA Solebury Trout
+ 1-646-438-9754 + 1-973-441-9731
[email protected] [email protected]

Media contact:
Catherine vincent
Consulting and KV management
+ 1-310-403-8951
[email protected]


Previous Cathay General Bancorp (NASDAQ: CATY) is expected to post quarterly sales of $ 166.37 million
Next Bald eagle camera uploaded to US steel mill in West Mifflin